Copyright
©The Author(s) 2022.
World J Gastroenterol. Dec 14, 2022; 28(46): 6497-6511
Published online Dec 14, 2022. doi: 10.3748/wjg.v28.i46.6497
Published online Dec 14, 2022. doi: 10.3748/wjg.v28.i46.6497
Stage | Progression | Metastasis |
0 | Unusual abnormal cells arise from mucosa of the colonic wall, eventually becoming cancerous and known as carcinoma in situ or intramucosal carcinoma | No |
I | Cancerous cells spread from the mucosa to submucosa and may also extended until the muscularis propria | No |
II | ||
IIA | Cancerous cells spread out from the submucosa to serosa (outermost layer) of the colon wall | No |
IIB | Cancerous cells spread through serosa but are not extended to nearby organs | No |
IIC | Cancerous cells spread to nearby organs | No |
III | ||
IIIA | In the first case, cancerous cells grow through the mucosa into submucosa and also may extended until the muscularis propria. The cancer spread to 1 to 3 nearby lymph nodes or into the areas of fat near lymph nodes but not to distant sites | No |
In the second case, the cancer has spread through the mucosa into submucosa and has spread to 4 to 6 nearby lymph nodes | ||
IIIB | In the first case, cancerous cells have spread through the muscularis propria of colon and/or rectum up to serosa or through the serosa to tissues and visceral peritoneum. They have also spread to 1 to 3 nearby lymph nodes or cancer cells are present in nearby tissues of lymph nodes but have not spread to distant sites | No |
Second case, the cancer has spread into the muscularis propria or into the outermost layers of colon or rectum and has spread to 4 to 6 nearby lymph nodes but not to distant sites | ||
Third case, the cancer has spread through the mucosa into submucosa and it might also have grown into the muscularis propria of colon and/or rectum and has spread to 7 or more nearby lymph nodes but not to distant sites | ||
IIIC | First case, the cancer has grown through the serosa colon and/or rectum to visceral peritoneum but has not reached nearby organs. It has spread to 4 to 6 nearby lymph nodes but not to distant sites | No |
Second case, the cancer has grown into the outermost layers of the colon and/or rectum or through visceral peritoneum but has not reached nearby organs. It has spread to 7 or more nearby lymph nodes but not to distant sites | ||
Third case, the cancer has grown through the wall of the colon and/or rectum and is attached to or has grown into other nearby tissues or organs. It has spread to at least one nearby lymph node or into areas of fat near the lymph nodes but not to distant sites | ||
IV | ||
IVA | The cancer has spread to one area or organ that is not near the colon and/or rectum, may be liver, lung, ovary, or a distant lymph node | Yes |
IVB | The cancer has spread to more than one area or organ that is not near the colon and/or rectum, such as the liver, lung, ovary, or a distant lymph node | Yes |
IVC | The cancer has spread to the tissue that lines the wall of the abdomen and may have spread to other areas or organs | Yes |
Ref. | Screening methods | |
[18-20] | Stool tests | Kit-based technique; guaiac-based fecal occult blood test uses guaiac to detect heme; FIT uses antibody to detect hemoglobin in stool; FIT-DNA test detects hemoglobin and DNA biomarkers in the stool |
Non-invasive, low cost, colon cleansing is not required, non-bleeding tumors cannot be detected | ||
[21,22] | Flexible sigmoidoscopy | Flexible tube with light, lens for viewing and tool for removing tissue; rectum and lower third of the colon screened to detect polyps, cancer or other abnormalities |
Sedation is required; accurate detection if polyps and cancers are present; unable to detect polyps or any abnormalities present in cecum, ascending colon hepatic flexure, or on transverse colon; colon cleansing is required | ||
[23,24] | Colonoscopy | Flexible tube light with a lens for seeing and a tool for excising the abnormal tissue; entire colon and rectum are screened for cancer by inserting the colonoscope through anus |
Sedation is required; visualization of entire inner lining of the colon and rectum; minute polyps can be detected; sedation may lead to bleeding or tear of the intestinal wall; sedation may lead to bleeding or tear of the intestinal wall | ||
[25-27] | Computed tomography colonography | X-ray based computed tomography scanner captures two- and three-dimensional images of the entire colon; computer assembles these pictures into detailed images |
Sedation is not required in this method; non-invasive; colon cleansing is not essential; may miss small polyps | ||
[28] | Double-contrast barium enema | X-ray images are then captured by introducing barium sulphate enema |
Examination of the whole colon and the rectum; sedation is not required; for the patient who cannot undergo standard colonscopy, this method is useful; colon cleansing is very necessary for this method; otherwise, it will give false positive results |
Treatment methods | Types/medication details | Side-effects | Stages | Ref. |
Surgery | Laparoscopic surgery | Pain; tenderness; irritation and itching; constipation or diarrhea | I, II, III, IV | [32,44] |
Colostomy for rectal cancer | ||||
Radiofrequency ablation or cryoablation | ||||
Radiation therapy | External-beam radiation therapy | Fatigue; mild skin reactions; bleeding in stools; constipation or diarrhea; infertility | II, III, IV | [33,34] |
Stereotactic radiation therapy | ||||
Intraoperative radiation therapy | ||||
Brachytherapy | ||||
Chemotherapy | Capecitabine (Xeloda) | Vomiting; nausea; diarrhea; mouth sores; neuropathy; fatigue; hair loss | II, III, IV | [36,39] |
Fluorouracil | ||||
Irinotecan (Camptosar) | ||||
Oxaliplatin (Eloxatin) | ||||
Trifluridine/tipiracil (Lonsurf) | ||||
Targeted therapy | Anti-angiogenesis therapy | Rashes | IV | [38,45] |
Epidermal growth factor receptor inhibitors | ||||
Combined targeted therapies | ||||
Tumor-agnostic treatment | ||||
Immunotherapy | Pembrolizumab (Keytruda) | Fatigue; rashes, pain and itching; diarrhea; nausea; fever; vomiting; shortness of breath | III, IV | [46,47] |
Nivolumab (Opdivo) | ||||
Dostarlimab (Jemperli) | ||||
Nivolumab and ipilimumab (Yervoy) combination |
- Citation: Gogoi P, Kaur G, Singh NK. Nanotechnology for colorectal cancer detection and treatment. World J Gastroenterol 2022; 28(46): 6497-6511
- URL: https://www.wjgnet.com/1007-9327/full/v28/i46/6497.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i46.6497